To develop and maintain a database of de-identified patient medical information and other related information in order to better assess and optimize outcomes for patients diagnosed with PAH and receiving treatment with Uptravi®.
Age Group: Patients ≥ 18 years of age at time of Uptravi initiation.
National Clinical Trial (NCT) identifier on clinicaltrials.gov: NCT03278002
Inova Heart and Vascular Institute, Advanced Lung Disease and Transplant Clinic, 3300 Gallows Road, Falls Church, VA 22042
Oksana Shlobin, MD
Eligibility Information (brief)
- Signed patient ICF.
- Patients with PAH who either initiate Uptravi at the time of enrollment or have been receiving treatment with Uptravi and have a documented titration regimen (defined as all documented dose changes including, but not limited to: starting dose and highest tolerated dose).
Ineligibility information (brief)
- Patients previously exposed to Uptravi treatment during a clinical trial.